Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050045192 A1
Publication typeApplication
Application numberUS 10/943,434
Publication dateMar 3, 2005
Filing dateSep 16, 2004
Priority dateJun 22, 1998
Also published asDE69942833D1, EP1096875A1, EP1096875A4, EP1096875B1, EP2258258A2, EP2258258A3, EP2258258B1, US6270464, US6699205, US6730042, US8292822, US20010049481, US20020058883, US20040204660, US20040210160, US20050033195, US20060079829, WO1999066834A1
Publication number10943434, 943434, US 2005/0045192 A1, US 2005/045192 A1, US 20050045192 A1, US 20050045192A1, US 2005045192 A1, US 2005045192A1, US-A1-20050045192, US-A1-2005045192, US2005/0045192A1, US2005/045192A1, US20050045192 A1, US20050045192A1, US2005045192 A1, US2005045192A1
InventorsRichard Fulton, William Dubrul
Original AssigneeArtemis Medical, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Biopsy localization method and device
US 20050045192 A1
Abstract
Biopsy localization devices and methods made according to the invention include a bioresorbable body, such as a gelatin, polylactic acid, and/or polyglycolic acid. The bioresorbable body preferably carries a radiopaque marker. The bioresorbable body preferably swells to fill the biopsied open region. The bioresorbable body and radiopaque marker permit the biopsy site to be relocated by various techniques, including mammography and ultrasound.
Images(4)
Previous page
Next page
Claims(24)
1. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising gelatin; and
a radiopaque marker carried by the bioresorbable body.
2. The target tissue localization device of claim 1, wherein the bioresorbable body is remotely visualizable by at least one of ultrasound and mammography.
3. The target tissue localization device of claim 1, wherein the radiopaque marker is contained within the bioresorbable body.
4. The target tissue localization device of claim 1, wherein the bioresorbable body comprises at least one bioresorbable body.
5. The target tissue localization device of claim 1, wherein the bioresorbable body swells upon contact with body fluid.
6. The target tissue localization device of claim 5, wherein the bioresorbable body swells to substantially fill the biopsy site.
7. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising gelatin;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
8. The method of claim 7, further comprising the step of relocating the biopsy site by detecting the radiopaque marker.
9. The method of claim 7, wherein the bioresorbable body comprises at least one bioresorbable body.
10. The method of claim 7, wherein the radiopaque marker is contained within the bioresorbable body.
11. The method of claim 7, wherein the radiopaque marker is detected by mammography.
12. The method of claim 7, wherein the radiopaque marker is detected by ultrasound.
13. The method of claim 7, wherein the bioresorbable body swells upon contact with body fluid.
14. The method of claim 7, wherein the bioresorbable body swells to substantially fill the biopsy site.
15. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polylactic acid; and
a radiopaque marker carried by the bioresorbable body.
16. The target tissue localization device of claim 15, wherein the bioresorbable body further comprises polyglycolic acid.
17-21. (Canceled)
22. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polylactic acid;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
23. The method of claim 22, wherein the bioresorbable body further comprises polyglycolic acid.
24-30. (Canceled)
31. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polyglycolic acid; and
a radiopaque marker carried by the bioresorbable body.
32-37. (Canceled)
38. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polyglycolic acid;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
39-46. (Canceled)
Description
  • [0001]
    This application is a continuation of U.S. application Ser. No. 10/839,112, filed May 4, 2004, which is a continuation of U.S. application Ser. No. 10/027,157, filed Dec. 20, 2001, now issued as U.S. Pat. No. 6,730,042, which is a continuation of U.S. application Ser. No. 09/900,801, filed Jul. 6, 2001, now issued as U.S. Pat. No. 6,699,205, which is a continuation of U.S. application Ser. No. 09/336,360, filed Jun. 18, 1999, now issued as U.S. Pat. No. 6,270,464, which application claims the benefit of the following Provisional patent applications: Biopsy Localization Device, Application No. 60/090,243, filed Jun. 22, 1998; Biopsy Localization and Hemostasis Device, Application No. 60/092,734, filed Jul. 14, 1998; Device and Method of Biopsy Localization and Hemostasis, Application No. 60/114,863, filed Jan. 6, 1999; and Device and Method of Biopsy Localization, Hemostasis & Cancer Therapy, Application No. 60/117,421, filed Jan. 27, 1999, all of which are herein expressly incorporated by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • [0002]
    In the U.S. alone approximately one million women will have breast biopsies because of irregular mammograms and palpable abnormalities. See FIG. 1 which diagrams the current treatment algorithm for non-palpable breast lesions. Biopsies can be done in a number of different ways for non-palpable lesions, including surgical excisional biopsies and stereotactic and ultrasound guided needle breast biopsies. In the case of image directed biopsy, the radiologist or other physician takes a small sample of the irregular tissue for laboratory analysis. If the biopsy proves to be malignant, additional surgery (typically a lumpectomy or a mastectomy) is required. The patient then returns to the radiologist a day or two later where the biopsy site (the site of the lesion) is relocated by method called needle localization, a preoperative localization in preparation for the surgery.
  • [0003]
    Locating the previously biopsied area after surgical excision type of biopsy is usually not a problem because of the deformity caused by the surgery. However, if the biopsy had been done with an image directed needle technique, as is common, help in relocating the biopsy site is usually needed. One procedure to permit the biopsy site to be relocated by the radiologist during preoperative localization is to leave some of the suspicious calcifications; this has its drawbacks.
  • [0004]
    Another way to help the radiologist relocate the biopsy site involves the use of a small metallic surgical clip, such as those made by Biopsys. The metallic clip can be deployed through the biopsy needle, and is left at the biopsy site at the time of the original biopsy. With the metallic clip as a guide, the radiologist typically inserts a barbed or hooked wire, such as the Hawkins, Kopans, Homer, Sadowski, and other needles, back into the patient's breast and positions the tip of the wire at the biopsy site using mammography to document the placement. The patient is then taken to the operating room with the needle apparatus sticking out of the patient's breast. While the clip provides a good indication of the biopsy site to the radiologist during preoperative localization, the clip remains permanently within the 80% of patients with benign diagnoses. Also, because the clip is necessarily attached to a single position at the periphery of the biopsy site, rather than the center of the biopsy site, its location may provide a misleading indication of the location of diseased tissue during any subsequent medical intervention. In addition, the soft nature of breast tissue permits the tip of the barbed or hooked needle to be relatively easily dislodged from the biopsy site. The clip is also relatively expensive.
  • [0005]
    Another localization method involves the use of laser light from the tip of a optical fiber connected to a laser. A pair of hooks at the tip of the optical fiber secures the tip at the biopsy site; the glow indicates the position of the tip through several centimeters of breast tissue. This procedure suffers from some of the same problems associated with the use of barbed or hooked wires. Another preoperative localization procedure injects medical-grade powdered carbon suspension from the lesion to the skin surface. This procedure also has certain problems, including the creation of discontinuities along the carbon trail.
  • SUMMARY OF THE INVENTION
  • [0006]
    The present invention is directed to a biopsy localization method and device which uses a locatable bioabsorbable element left at the biopsy site so that if testing of the biopsy sample indicates a need to do so, the biopsy site can be relocated by finding the bioabsorbable element. This eliminates the need to use of metallic clips during biopsies and often eliminates the need for a return to the radiologist for preoperative needle localization. In addition, the bioabsorbable element can be used as a therapeutic tool for treatment of the diseased lesion and for hemostasis.
  • [0007]
    A biopsy localization device made according to the invention includes a bioabsorbable element delivered in a pre-delivery state to a soft tissue biopsy site of a patient by an element delivery device. The bioabsorbable element may be palpably harder than the surrounding soft tissue at the biopsy site when in the post-delivery state.
  • [0008]
    One preferred material used as the bioabsorbable element is a dehydrated collagen plug. This type of plug may swell and is palpable for subsequent location by the surgeon. The collagen plug may not swell at all. In some situations, such as with small breasted women or where the biopsy site is close to the surface, a non-swellable bioabsorbable material, such as a round pellet of PGA, can be used instead of a swellable bioabsorbable material. The bioabsorbable material can also be made so that it is absorbed quickly to produce a local tissue inflammation; such a localized inflammation can be used to locate the biopsy site instead of location by palpation. Instead of leaving, for example, a collagen plug, a PGA pellet or a bioabsorbable suture material at the biopsy site for location by palpation or inflammation, a length of bioabsorbable suture material, a collagen filament, or other bioabsorbable material extending from the biopsy site out through the skin can be used. In this case the surgeon can follow the bioabsorbable suture material to the biopsy site in a manner similar to that used with Hawkins needles. In other cases, such as in the case of a deeply located lesion or large breast, the bioabsorbable material may need to be located by the radiologist, by for example, ultrasound or mammography. In any event the bioabsorbable material will typically be absorbed within about a month of placement. The invention thus eliminates the use of metal clips during biopsies and usually eliminates the need for return to the radiologist for preoperative localization.
  • [0009]
    While the primary use of the device is intended to localize the site of needle biopsies for possible future surgical excision, the device may also be useful in marking the site of surgical excisional biopsies. For example, during a wide surgical excision for cancer diagnosed by a recent surgical excisional biopsy, surgeons frequently have difficulty in determining the precise relationship of the previously excised tissue to the surgical wound. Therefore, more tissue is removed than might have been removed had the exact location of the previous lesion been more definite. With the present invention, a bioabsorbable element may be inserted into the biopsy site during a surgical excisional biopsy before the wound is closed to mark the site for potential wide excision should the biopsy reveal cancer. Alternatively, a bioabsorbable element may be placed at the biopsy site using a delivery device by partially or completely closing the wound and then depositing the bioabsorbable element through the delivery device and removing the delivery device through the closed incision. The presence of the palpable marker within the previous excisional biopsy site would allow the surgeon to more easily and confidently remove tissue around this site, and preserve more normal breast tissue.
  • [0010]
    Another use of the device is to primarily localize a non-palpable lesion prior to surgical excisional biopsy. Instead of using the needle/wire apparatus which has a tendency to migrate and become dislodged with traction, the palpable marker may be inserted into the suspicious area of the breast under mammographic or ultrasonic guidance immediately prior to the surgical excisional biopsy. This would provide a palpable locator for the surgeon as described above. In this instance, the marker would only need to be palpable, and not necessarily bioresorbable, since the intent would be to remove it in all cases.
  • [0011]
    In addition to permitting the biopsy site to be located by subsequent palpation or other means, the invention also can provide hemostasis and therapeutic benefits. The bioabsorbable element may comprise a therapeutic agent; the therapeutic agent may comprise at least a chosen one of a chemotherapeutic agent, a radiation agent and a gene therapy agent. Since the bloabsorbability can be varied from a day or two to a year or more, the material may be used to treat the diseased tissue and not just locate it. Some current therapies include radiation, chemotherapy, gene therapy as well as other technologies and therapies. Because the bioabsorbability can be easily varied, a medium can be place into the bioabsorbable element and be externally excited or triggered in those cases where the biopsy results are malignant. Further, the bioabsorbability concept can be used for future implantation of a therapeutic agent. For example, if the bioabsorbable element is a dehydrated collagen, this material could be used as a reservoir for, for example, delivery of materials that effect chemotherapy, brachytherapy, etc. Once the laboratory results are received and show the biopsy is malignant and therapy is required, by surgical excision or otherwise, the physician may inject, for example, a radiation pellet, a chemotherapeutic agent or a gene therapeutic agent into or adjacent to the bioabsorbable element for direct treatment of the diseased tissue.
  • [0012]
    The change in the bioabsorbable element can be via one of several ways, such as hydration or desiccation, change in temperature, electrical stimulation, magnetic stimulation, chemical or physical reaction with another material, additives, enzymatic reactions, ionization, electrical charges, absorption, as well as other means. The invention may employ one or more of these techniques or measures or others, to change the consistency, hardness and or size of the bioabsorbable element between its deployed and non-deployed states. The visual detectability of the bioabsorbable element may be aided by the use of a coloring agent, such as methylene blue or some other dye. The radiographic detectability of the element may be enhanced by a radiopaque marker. As well, ultrasonic detectability may be enhance by special treatment of the bioresorbable element.
  • [0013]
    The bioresorbable element may have margins which are roughened so as to prevent migration within the tissues. Filaments extending from the margins of the bioresorbable element may be utilized also to stabilize the position of the device within the cavity. The filaments may or may not be composed of the same material as the bioresorbable element.
  • [0014]
    The provision of hemostasis helps to lessen the bleeding and swelling within and about the biopsy site. This can be accomplished by physical or chemical means. That is, the device may swell so that it essential fills the biopsy cavity or the device may have a chemical reaction with blood or blood products to cause effective blood clotting, or both. Other methods for causing local hemostasis are also possible with the invention.
  • [0015]
    Other features and advantages of the invention will appear from the following description in which the preferred embodiments and methods have been set forth in detail in conjunction with the accompany drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    FIG. 1 is a flow diagram of a conventional treatment algorithm for nonpalpable breast lesions;
  • [0017]
    FIG. 2 is a flow diagram of a treatment algorithm according to the present invention;
  • [0018]
    FIG. 3 is a simplified view illustrating a biopsy needle assembly obtaining a tissue sample of an abnormality at a target site;
  • [0019]
    FIG. 4 illustrates the main housing and sheath of the needle biopsy assembly left in place after the tissue sample has been removed leaving a biopsied open region at the target site;
  • [0020]
    FIG. 5 illustrates the barrel of the delivery device of FIG. 4 inserted into the main housing of the biopsy needle assembly and the plunger depressed injecting the bioabsorbable element into the biopsied open region, thus effectively filling the biopsied open region at the target site;
  • [0021]
    FIG. 6 illustrates the location of the bioabsorbable element of FIG. 5 with the surgeon using his or her fingers; and
  • [0022]
    FIG. 7 illustrates a bioabsorbable thread extending from the bioabsorbable element of FIG. 5 up through the patient's skin, the thread being delivered to the bioabsorbable element using the delivery device of FIGS. 4 and 5.
  • DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • [0023]
    FIG. 2 illustrates a treatment algorithm 2 according to the present invention. As a result of a routine mammography 4, a tumor or other abnormality may be detected as at 6. The typical response will often include additional magnification mammograms or a follow-up mammogram scheduled for some time in the future, such as six months. This is indicated at 8. If the tumor is not palpable, see 9, an image guided needle biopsy by a breast radiologist is typically conducted as at 10. Image guided needle biopsies can be done in a number of ways. Presently, stereotactic (x-ray) and ultrasound guided needle biopsies are commonly used, primarily because of their accuracy, speed and minimal trauma to the patient. Stereotactic needle biopsies typically use a stereotactic table, such as made by Fisher or Lorad, which provides mammography (x-ray) guidance to a biopsy needle assembly. Ultrasound guided biopsies can be conducted with any one of a number of commercially available instruments. An exemplary biopsy needle assembly 14, illustrated in FIG. 3, includes a biopsy needle 13 passing through a sheath 20 extending from a hollow main housing 22. The tip 12 of biopsy needle 13 of biopsy needle assembly 14 is automatically inserted to the abnormality 16 at the target site 18. Biopsy needle 13 has a laterally directed side opening 24 adjacent to tip 12 used to capture a tissue sample of abnormality 16. Once the tissue samples have been obtained, the removed tissue creates a biopsied open region 26 at target site 18. See FIG. 4. Following the removal of biopsy needle 13 from sheath 20 and main housing 22, the barrel 30 of a bioabsorbable element delivery device 32 is inserted through main housing 22 and into sheath 20. Barrel 30 contains a bioabsorbable element 34, see FIG. 5 Bioabsorbable element 34 is, in this preferred embodiment, a plug of dehydrated collagen, such as that sold by several companies such as Davol, Datascope, Integra Life Sciences, Collagen Matrix, Vascular Solutions, et al. Bioabsorbable element 34 may swell on contact with an aqueous liquid within biopsied open region 26 and substantially fills the biopsied open region as suggested in FIG. 5. In this preferred embodiment, bioabsorbable element 34 is transformed from its pre-delivery state within barrel 30 to its post-delivery state at region 26 and in the process swells and becomes somewhat softer in its post-delivery state than in its pre-delivery state. However, in its post-delivery state, bioabsorbable element 34 is palpably harder, preferably at least about 1.5 times harder, than the surrounding soft tissue, typically breast tissue 36. This permits bioabsorbable element 34 at the target site 18 to be relocated by palpation of the patient by the physician, see FIG. 6, to find the bioabsorbable element 6 and as discussed in more detail below.
  • [0024]
    A bioabsorbable element could be made of materials other than collagen and could be in a form other than a solid, relatively hard plug in its pre-delivery state. For example, bioabsorbable element 34 in its pre-delivery state within barrel 30 could be in a liquid or otherwise flowable form; after being deposited at open region 26 at target site 18, the bioabsorbable element could change to become palpably harder than the surrounding tissue 36 to permit subsequent relocation of target site 18 by palpation. In some situations, it may be desired that bioabsorbable element 34 not change its size or hardness between its pre-delivery state and its post-delivery state, such as being palpably harder than the surrounding tissue 36 in both states. In a preferred embodiment, transformation of bioabsorbable element 34 is by contact with an aqueous liquid.
  • [0025]
    However, transformation of the bioabsorbable element, which can be in terms of, for example, hardness, texture, shape, size, or a combination thereof, can be due to other factors, such as application of thermal energy, radiation, magnetic energy, etc.
  • [0026]
    Returning again to FIG. 2, it is seen that after insertion of bioabsorbable element 34, the biopsy sample is sent to pathology for evaluation at 36. If the pathology report, which is available a day or two after the biopsy, is benign, the patient is so informed and the bioabsorbable element simply is absorbed by the patient within, for example, a month as at 38. If the pathology report is positive, so that cancer is found, the biopsied open region 26 at the target site 18 is located by the surgeon by palpation as suggested by FIG. 6. After finding the target site by palpation, which eliminates the need for preoperative localization by the radiologist, appropriate medical treatment, such as excisional surgery, can be performed.
  • [0027]
    If the tumor is palpable, the surgeon may choose to make a direct incisional biopsy as at 48. According to the present invention, bioabsorbable delivery device 32 could be used to place bioabsorbable element 34 at the site of the incisional biopsy. After removal of delivery device 32, the incision would be closed, the biopsy sample would be sent to pathology and the patient would go home with the procedure preceding as discussed above, starting with item 36.
  • [0028]
    It may be preferred that bioabsorbable element 34 also act as a hemostatic agent to stop bleeding at site 18 by virtue of physical means, by filling or substantially filling open region 26, as well as chemical means through the chemical interaction, such as coagulation, with blood components. In addition, bioabsorbable element 34 could be covered by a non-hemostatic degradable outer layer so that hemostasis or other action is delayed until the outer layer has been eroded. In some situations, it may be necessary or at least desirable to shield the bioabsorbable element from the blood or other body fluids until after the bioabsorbable element is in place at target site 18. This could be accomplished by, for example, physically isolating the bioabsorbable element from body fluids by using a removable physical barrier during delivery of the bioabsorbable element. Alternatively, a bioabsorbable coating or layer, as described above, may be used. The bioabsorbable element may be changed from its pre-delivery state to its post-delivery state in a variety of manners including hydration, changing the temperature, electrical stimulation, magnetic stimulation, chemical reaction with a stimulating agent, physically interaction with an activating member (such as a knife blade which could be used to slice open a capsule containing the bioabsorbable element), by ionizing the bioabsorbable element, or by absorption or adsorption of a fluid by the bioabsorbable element.
  • [0029]
    The invention may also be used to medically treat the patient. That is, the bioabsorbable element-could include a therapeutic element which would be activated only if the pathology report indicated the need for the medical treatment. Various ways of activating an agent in a bioabsorbable element could be used, such as injecting a radiation-emitting element at the vicinity of the target site, externally irradiating the target site, providing a triggering substance to the target site, manual pressure, photodynamic therapy, sclerosing chemistry, vibrational therapy, ultrasound, and the like. Alternatively, the bioabsorbable element could be made so that it includes no such activating agent; rather, medical treatment could be provided by, for example, delivery of a chemotherapy agent, a radiation emitting element, thermal energy, electrical energy, vibrational energy, gene therapy, vector therapy, anti-angiogenesis therapy. To facilitate the delivery, the bioabsorbable element may contain a radiopaque marker or may have properties to aid in detecting it by ultrasound, in addition to being palpable.
  • [0030]
    An important use for the invention is in the treatment of breast cancer. In one embodiment, it is desirable that bioabsorbable element 34 in its post-delivery state have a hardness of at least about one and a half times that of breast tissue so that it is palpably harder than the surrounding tissue. Also, it is desired that bioabsorbable element 34, in one embodiment, swells from its pre-delivery state to its post-delivery state so to fill or at least substantially fills open region 26. To achieve this it is preferred that bioabsorbable element 34 swells about 50 to 1500%, and more preferably about 100 to 300%, from the pre-delivery state to the post delivery state, typically when placed in contact with an aqueous liquid. It is preferred that the bioabsorbable element has a longest dimension of at least about 0.5 cm in its post-delivery state to aid its location by palpation.
  • [0031]
    While the bioabsorbable element is preferably made of collagen in one embodiment, the bioabsorbable element can include, for example, one or more of the following materials; polyactic and polyglycolic acids, polyorthoesters, resorbable silicones and urethanes, lipids, polysaccharides, starches, ceramics, polyamino acids, proteins, hydrogels and other gels, gelatins, polymers, cellulose, elastin, and the like.
  • [0032]
    In some situations it may be desired to use a bioabsorbable filament 44 extending from bioabsorbable element 34 through the patient's skin 46 as shown in FIG. 7. This can be accomplished by delivering bioabsorbable filament 44 through sheath 20 as bioabsorbable element 34 is injected into region 26 at target site 18. In some situations it may not be possible or desirable to use bioabsorbable element 34; in those situations it may be useful to provide for only bioabsorbable filament 44 extending from target site 18 to above the patient's skin 46.
  • [0033]
    While it is presently preferred that bioabsorbable element delivery device 32 be guided through a portion of needle assembly 14, that is sheath 20 and main housing 22, in some situations it may be useful to cover sheath 20 with an outer sheath which would be left in place after the biopsy sample has been removed and the entire biopsy needle assembly 14 has been removed. The sheath left in place would then be used to guide barrel 30 of delivery device 32 to target site 18. Of course, delivery device 32 could take a number of different forms such as a syringe containing fluid or paste that is injected through a needle or through the housing 22 and sheath 20 or through an outer sheath. Alternatively, other delivery devices could be employed for delivery of bioresorbable element 34.
  • [0034]
    The invention has applicability toward the correction of a defect that is caused by breast tissue removal for biopsy or diseased tissue removal. Collagen is often placed in the body where it is eventually replaced by human autogenous tissue. Hence, the invention could be used for the repair of tissue that has been damaged due to tissue removal. The delivery device described heretofore could be used for installing a material (synthetic or mammalian) into the cavity for such a cosmetic or reconstructive repair. The material would typically be an effectively non-bioabsorable material, such as a silicon gel-filled capsule or bag.
  • [0035]
    Modification and variation can be made to the disclosed embodiments without departing from the subject of the invention as defined in the following claims.
  • [0036]
    Any and all patents, patent applications, and printed publications referred to above are incorporated by reference.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3818894 *Jan 3, 1972Jun 25, 1974Ceskoslovenska Akademie VedLaryngeal implant
US4007732 *Sep 2, 1975Feb 15, 1977Robert Carl KvavleMethod for location and removal of soft tissue in human biopsy operations
US4248214 *May 22, 1979Feb 3, 1981Robert S. KishIlluminated urethral catheter
US4331654 *Jun 13, 1980May 25, 1982Eli Lilly And CompanyMagnetically-localizable, biodegradable lipid microspheres
US4541438 *Jun 2, 1983Sep 17, 1985The Johns Hopkins UniversityLocalization of cancerous tissue by monitoring infrared fluorescence emitted by intravenously injected porphyrin tumor-specific markers excited by long wavelength light
US4545367 *Nov 18, 1983Oct 8, 1985Cordis CorporationDetachable balloon catheter and method of use
US4592356 *Sep 28, 1984Jun 3, 1986Pedro GutierrezLocalizing device
US4647480 *Aug 1, 1985Mar 3, 1987Amchem Products, Inc.Use of additive in aqueous cure of autodeposited coatings
US4655211 *Aug 8, 1985Apr 7, 1987Unitika Ltd.Hemostatic agent
US4693237 *Jan 21, 1986Sep 15, 1987Hoffman Richard BRadiopaque coded ring markers for use in identifying surgical grafts
US4763642 *Apr 7, 1986Aug 16, 1988Horowitz Bruce SIntracavitational brachytherapy
US4774948 *Nov 24, 1986Oct 4, 1988Markham Charles WMarking and retraction needle having retrievable stylet
US4799495 *Mar 20, 1987Jan 24, 1989National Standard CompanyLocalization needle assembly
US4813422 *Mar 6, 1987Mar 21, 1989Healthcare Technological Resources, Inc.Bowel control probe and method for controlling bowel incontinence
US4817622 *Jul 22, 1986Apr 4, 1989Carl PennypackerInfrared imager for viewing subcutaneous location of vascular structures and method of use
US4838280 *May 26, 1988Jun 13, 1989Haaga John RHemostatic sheath for a biopsy needle and method of use
US4847049 *Mar 20, 1987Jul 11, 1989Vitaphore CorporationMethod of forming chelated collagen having bactericidal properties
US4852568 *Dec 28, 1987Aug 1, 1989Kensey Nash CorporationMethod and apparatus for sealing an opening in tissue of a living being
US4909250 *Nov 14, 1988Mar 20, 1990Smith Joseph RImplant system for animal identification
US4966583 *Feb 3, 1989Oct 30, 1990Elie DebbasApparatus for locating a breast mass
US4986279 *Mar 1, 1989Jan 22, 1991National-Standard CompanyLocalization needle assembly with reinforced needle assembly
US5014713 *Dec 5, 1989May 14, 1991Tarris Enterprises, Inc.Method and apparatus for measuring thickness of fat using infrared light
US5018530 *Jun 15, 1989May 28, 1991Research Corporation Technologies, Inc.Helical-tipped lesion localization needle device and method of using the same
US5080655 *Apr 26, 1990Jan 14, 1992Haaga John RMedical biopsy needle
US5083570 *Jun 18, 1990Jan 28, 1992Mosby Richard AVolumetric localization/biopsy/surgical device
US5158084 *Nov 22, 1989Oct 27, 1992Board Of Regents, The University Of Texas SystemModified localization wire for excisional biopsy
US5195988 *Nov 4, 1991Mar 23, 1993Haaga John RMedical needle with removable sheath
US5197482 *Apr 2, 1991Mar 30, 1993Research Corporation Technologies, Inc.Helical-tipped lesion localization needle device and method of using the same
US5221269 *Oct 15, 1990Jun 22, 1993Cook IncorporatedGuide for localizing a nonpalpable breast lesion
US5236410 *Mar 11, 1991Aug 17, 1993Ferrotherm International, Inc.Tumor treatment method
US5281408 *Jan 19, 1993Jan 25, 1994Unger Evan CLow density microspheres and their use as contrast agents for computed tomography
US5282781 *Oct 25, 1990Feb 1, 1994Omnitron International Inc.Source wire for localized radiation treatment of tumors
US5325857 *Jul 9, 1993Jul 5, 1994Hossein NabaiSkin biopsy device and method
US5334216 *Dec 10, 1992Aug 2, 1994Howmedica Inc.Hemostatic plug
US5334381 *Jun 30, 1993Aug 2, 1994Unger Evan CLiposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5342283 *Aug 13, 1990Aug 30, 1994Good Roger REndocurietherapy
US5353804 *Mar 17, 1993Oct 11, 1994Peb Biopsy CorporationMethod and device for percutaneous exisional breast biopsy
US5388588 *May 4, 1993Feb 14, 1995Nabai; HosseinBiopsy wound closure device and method
US5394886 *Sep 20, 1993Mar 7, 1995Nabai; HosseinSkin biopsy plug and method
US5409004 *Apr 6, 1994Apr 25, 1995Cook IncorporatedLocalization device with radiopaque markings
US5411520 *Feb 3, 1993May 2, 1995Kensey Nash CorporationHemostatic vessel puncture closure system utilizing a plug located within the puncture tract spaced from the vessel, and method of use
US5422730 *Mar 25, 1994Jun 6, 1995Barlow; Clyde H.Automated optical detection of tissue perfusion by microspheres
US5423321 *Feb 2, 1994Jun 13, 1995Fontenot; Mark G.Detection of anatomic passages using infrared emitting catheter
US5467780 *Dec 19, 1994Nov 21, 1995Nabai; HosseinBiopsy wound closure device and method
US5479936 *Dec 19, 1994Jan 2, 1996Nabai; HosseinBiopsy wound closure device and method
US5483972 *Dec 19, 1994Jan 16, 1996Nabai; HosseinBiopsy wound closure device
US5487392 *Nov 15, 1993Jan 30, 1996Haaga; John R.Biopxy system with hemostatic insert
US5494030 *Aug 12, 1993Feb 27, 1996Trustees Of Dartmouth CollegeApparatus and methodology for determining oxygen in biological systems
US5517997 *Sep 15, 1994May 21, 1996Gabriel Medical, Inc.Transillumination of body members for protection during body invasive procedures
US5526822 *Mar 24, 1994Jun 18, 1996Biopsys Medical, Inc.Method and apparatus for automated biopsy and collection of soft tissue
US5549560 *May 13, 1993Aug 27, 1996Wijdeven Gijsbertus G P Van DeApparatus and method for injecting a pharmaceutical preparation in solid form
US5556410 *Sep 27, 1993Sep 17, 1996M3 Systems, Inc.Surgical needle with stress-relocation means
US5636255 *Mar 5, 1996Jun 3, 1997Queen's University At KingstonMethod and apparatus for CT image registration
US5643246 *Feb 24, 1995Jul 1, 1997Gel Sciences, Inc.Electromagnetically triggered, responsive gel based drug delivery device
US5646146 *May 25, 1995Jul 8, 1997Novo Nordisk A/SHeterocyclic compounds and their preparation and use
US5647374 *Dec 30, 1994Jul 15, 1997North American ScientificNeedle for imaging and sampling
US5660185 *Apr 13, 1995Aug 26, 1997Neovision CorporationImage-guided biopsy apparatus with enhanced imaging and methods
US5676925 *Jun 7, 1995Oct 14, 1997Nycomed Imaging AsContrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5688490 *Feb 7, 1996Nov 18, 1997Bracco International B.V.Mucoadhesive compositions for increasing the ultrasonic image contrast of the digestive tract
US5795308 *Jul 26, 1996Aug 18, 1998Russin; Lincoln D.Apparatus for coaxial breast biopsy
US5807276 *Jun 23, 1997Sep 15, 1998Russin; Lincoln DavidBiopsy device and method
US5873904 *Feb 24, 1997Feb 23, 1999Cook IncorporatedSilver implantable medical device
US5899935 *Aug 4, 1997May 4, 1999Schneider (Usa) Inc.Balloon expandable braided stent with restraint
US5902310 *Feb 21, 1997May 11, 1999Ethicon Endo-Surgery, Inc.Apparatus and method for marking tissue
US6053876 *Jun 9, 1999Apr 25, 2000Fisher; JohnApparatus and method for marking non-palpable lesions
US6056700 *Oct 13, 1998May 2, 2000Emx, Inc.Biopsy marker assembly and method of use
US6071301 *May 1, 1998Jun 6, 2000Sub Q., Inc.Device and method for facilitating hemostasis of a biopsy tract
US6161034 *Feb 2, 1999Dec 12, 2000Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6183497 *Jun 17, 1999Feb 6, 2001Sub-Q, Inc.Absorbable sponge with contrasting agent
US6214045 *Oct 9, 1998Apr 10, 2001John D. Corbitt, Jr.Bioabsorbable breast implant
US6228055 *May 19, 1997May 8, 2001Ethicon Endo-Surgery, Inc.Devices for marking and defining particular locations in body tissue
US6231834 *Dec 2, 1997May 15, 2001Imarx Pharmaceutical Corp.Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6248057 *Jul 27, 1999Jun 19, 2001Innerdyne, Inc.Absorbable brachytherapy and chemotherapy delivery devices and methods
US6270464 *Jun 18, 1999Aug 7, 2001Artemis Medical, Inc.Biopsy localization method and device
US6335028 *Mar 5, 1999Jan 1, 2002Biosphere Medical, Inc.Implantable particles for urinary incontinence
US6352662 *Aug 23, 1999Mar 5, 2002Callaway Golf CompanyIntegral molded grip and shaft
US6356782 *Apr 2, 1999Mar 12, 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US6427081 *Sep 5, 2000Jul 30, 2002Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6589502 *Nov 27, 1995Jul 8, 2003International Brachytherapy S.A.Radioisotope dispersed in a matrix for brachytherapy
US20020026201 *Sep 18, 2001Feb 28, 2002Foerster Seth A.Methods for defining and marking tissue
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7565191Jul 21, 2009Senorx, Inc.Tissue site markers for in vivo imaging
US7651505Jan 26, 2010Senorx, Inc.Plugged tip delivery for marker placement
US7792569 *Nov 16, 2004Sep 7, 2010Senorx, Inc.Cavity-filling biopsy site markers
US7877133Jan 25, 2011Senorx, Inc.Marker or filler forming fluid
US7970454Jun 18, 2008Jun 28, 2011Senorx, Inc.Marker delivery device with releasable plug
US7983734May 23, 2003Jul 19, 2011Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US8157862Dec 10, 2010Apr 17, 2012Senorx, Inc.Tissue marking implant
US8177792Nov 18, 2009May 15, 2012Senorx, Inc.Plugged tip delivery tube for marker placement
US8219182Jul 10, 2012Senorx, Inc.Cavity-filling biopsy site markers
US8224424Jul 13, 2009Jul 17, 2012Senorx, Inc.Tissue site markers for in vivo imaging
US8311610Jan 22, 2009Nov 13, 2012C. R. Bard, Inc.Biopsy tissue marker
US8361082Mar 1, 2011Jan 29, 2013Senorx, Inc.Marker delivery device with releasable plug
US8401622Dec 17, 2007Mar 19, 2013C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US8437834May 7, 2013C. R. Bard, Inc.Breast marker
US8447386Dec 14, 2010May 21, 2013Senorx, Inc.Marker or filler forming fluid
US8486028Sep 30, 2011Jul 16, 2013Bard Peripheral Vascular, Inc.Tissue marking apparatus having drug-eluting tissue marker
US8498693Apr 8, 2011Jul 30, 2013Senorx, Inc.Intracorporeal marker and marker delivery device
US8579931Sep 29, 2011Nov 12, 2013Bard Peripheral Vascular, Inc.Apparatus for the percutaneous marking of a lesion
US8626269Jun 8, 2011Jan 7, 2014Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US8626270Jun 13, 2012Jan 7, 2014Senorx, Inc.Cavity-filling biopsy site markers
US8634899Feb 3, 2006Jan 21, 2014Bard Peripheral Vascular, Inc.Multi mode imaging marker
US8639315May 16, 2013Jan 28, 2014Senorx, Inc.Marker or filler forming fluid
US8668737Mar 21, 2012Mar 11, 2014Senorx, Inc.Tissue marking implant
US8670818Dec 30, 2008Mar 11, 2014C. R. Bard, Inc.Marker delivery device for tissue marker placement
US8718745May 25, 2010May 6, 2014Senorx, Inc.Tissue site markers for in vivo imaging
US8784433Apr 27, 2012Jul 22, 2014Senorx, Inc.Plugged tip delivery tube for marker placement
US8880154Jul 19, 2013Nov 4, 2014Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US8965486Dec 6, 2013Feb 24, 2015Senorx, Inc.Cavity filling biopsy site markers
US9039763Jan 28, 2014May 26, 2015Senorx, Inc.Tissue marking implant
US9042965Mar 6, 2013May 26, 2015C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US9044162Jan 25, 2013Jun 2, 2015Senorx, Inc.Marker delivery device with releasable plug
US9149341Nov 21, 2011Oct 6, 2015Senorx, IncDeployment of polysaccharide markers for treating a site within a patient
US9237937Feb 20, 2015Jan 19, 2016Senorx, Inc.Cavity-filling biopsy site markers
US20030233101 *Jun 17, 2002Dec 18, 2003Senorx, Inc.Plugged tip delivery tube for marker placement
US20040236212 *May 23, 2003Nov 25, 2004Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US20040236213 *Jan 7, 2004Nov 25, 2004Senorx, Inc.Marker delivery device with releasable plug
US20050119562 *Oct 27, 2004Jun 2, 2005Senorx, Inc.Fibrous marker formed of synthetic polymer strands
US20050143656 *Nov 16, 2004Jun 30, 2005Senorx, Inc.Cavity-filling biopsy site markers
US20060036165 *Sep 29, 2005Feb 16, 2006Senorx, Inc.Tissue site markers for in vivo imaging
US20060155190 *Mar 2, 2006Jul 13, 2006Senorx, Inc.Imageable biopsy site marker
US20080039819 *Jul 26, 2007Feb 14, 2008Senorx, Inc.Marker formed of starch or other suitable polysaccharide
US20080058640 *Oct 30, 2007Mar 6, 2008Senoxrx, Inc.Marker formed of starch or other suitable polysaccharide
US20080254298 *May 29, 2008Oct 16, 2008Meadwestvaco CorporationMethod for treating a substrate
US20090030309 *Feb 21, 2008Jan 29, 2009Senorx, Inc.Deployment of polysaccharide markers
US20090131825 *Dec 18, 2008May 21, 2009Senorx, Inc.Imageable biopsy site marker
US20090287078 *Jun 24, 2008Nov 19, 2009Senorx, Inc.Marker or filler forming fluid
US20100010342 *Jul 13, 2009Jan 14, 2010Senorx, Inc.Tissue site markers for in vivo imaging
US20110237943 *Sep 29, 2011Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
USD715442Sep 24, 2013Oct 14, 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD715942Sep 24, 2013Oct 21, 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD716450Sep 24, 2013Oct 28, 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD716451Sep 24, 2013Oct 28, 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
Classifications
U.S. Classification128/899
International ClassificationA61B10/02, A61B19/00, A61B6/00, A61B17/34, A61B10/00
Cooperative ClassificationA61B2017/00004, A61B6/502, A61B17/3421, A61B10/02, A61B17/3468, A61B2090/3962, A61B2090/3987, A61B90/39, A61B2090/3908
European ClassificationA61B19/54
Legal Events
DateCodeEventDescription
Jul 13, 2010ASAssignment
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA
Free format text: SECURITY AGREEMENT;ASSIGNOR:ARTEMIS MEDICAL, INC.;REEL/FRAME:024672/0377
Effective date: 20100709